Viral Vector Manufacturing Success Stories: Onboarding to GMP Production

Life Sciences, Pharma Manufacturing & Supply Chain, Drug Discovery & Development, Cell and Gene Therapy,
  • Wednesday, February 07, 2024

Join this webinar to learn how to mitigate risk in viral vector manufacturing with tailored solutions and a flexible approach. Discover how unique and transferable technical capabilities in multiple viral vector types can significantly accelerate a development path and future-proof gene therapy products.

The featured experts will walk the attendees through the customer journey at Oxford Biomedica from client onboarding to the successful manufacture of adeno-associated virus (AAV) and lentiviral vectors. They will share success stories of optimized production processes and successful transfer into good manufacturing practice (GMP). Attendees will also hear about end-to-end automation of analytical assays and computer-aided biology strategies to enhance the development, bioprocessing and characterization of viral vectors for gene therapies.

A live Q&A session will follow the presentation, offering attendees a chance to pose questions to the team of experts.

Join this webinar to learn about successful case studies in viral vector manufacturing that use tailored solutions and a flexible approach.


Amy Barker, Oxford Biomedica

Amy Barker, PhD, Principal Scientist, Process Development, Oxford Biomedica

Amy Barker, PhD, is a Principal Scientist at Oxford Biomedica in the Process Development department. Her team is responsible for the initial onboarding of new client products to Oxford Biomedica, designing and performing initial feasibility studies tailored to client needs. These studies involve screening of multiple genomes, plasmid ratio assessments including Design of Experiment (DoE) strategies, and platform performance assessments with relevant analytic assays performed in both indicator cells and target primary cells. Prior to joining Oxford Biomedica, Dr. Barker gained extensive postdoctoral experience in a variety of areas, specializing in applying her understanding of cell and molecular biology to improving human health.

Message Presenter
Andre Raposo, Oxford Biomedica

Andre Raposo, PhD, Director, Innovation Department, Oxford Biomedica

Andre Raposo, PhD, is a Director at Oxford Biomedica in the Innovation department. He leads a group of scientists delivering cutting-edge research in the field of cell and gene therapy supported by computer-aided biology and high-throughput automation. He has extensive experience in technology development, upstream process development, DoE strategies, analytical development, robotics and associated regulatory compliance. Prior to Oxford Biomedica, Dr. Raposo worked within the Transduction Sciences CGT Platform CMC at GSK. Dr. Raposo holds a PhD from the University of Oxford and specialized in the understanding of host restriction factors controlling HIV replication and the mechanisms leading to HIV persistence and latency during his postdoc at the University of California San Francisco and the George Washington University in the USA.

Message Presenter
Hannah Boss, Oxford Biomedica

Hannah Boss, Director, Head of Quality Control, Oxford Biomedica

Hannah Boss is the Interim Head of Quality Control with responsibility for product quality testing, stability, contamination control and analytical method lifecycle management. She has 16 years of industry experience including roles in research, analytical development and quality control. Prior to Oxford Biomedica, Hannah was the head of Quality Control Molecular Biology for Homology Medicines, Inc. Hannah’s previous experience includes roles of increasing responsibility at Genzyme Corporation and bluebird bio. Hannah holds a BS degree in Biology from the University of Massachusetts Amherst and an MS degree in Biotechnology from Worcester State University.

Message Presenter

Who Should Attend?

  • Biotechnology and pharmaceutical professionals
  • Project Managers/Technical Experts
  • Business Development
  • Cell and gene therapy Program Leaders
  • Academics — Project Managers/Technical Experts

What You Will Learn

  • Client success stories from onboarding to GMP manufacturing of viral vectors for clinical use
  • Cutting-edge end-to-end automation of analytical assays and Design of Experiments to optimize vector production
  • Considerations for product comparability during process changes
  • Strategies to enhance viral vector production
  • Successful process transfer from PD (process development) to GMP operations involving cross-functional teams

Xtalks Partner

Oxford Biomedica

Oxford Biomedica is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. Oxford Biomedica collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica is headquartered in Oxford, UK with locations across Oxfordshire, UK and near Boston, MA, US. Learn more at and follow us on LinkedIn. (  

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account